

LEAMING NANCY  
Form 4  
May 27, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
LEAMING NANCY

(Last) (First) (Middle)

BIOGEN IDEC INC., 133 BOSTON POST ROAD

(Street)

WESTON, MA 02493

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
BIOGEN IDEC INC. [BIIB]

3. Date of Earliest Transaction (Month/Day/Year)  
05/26/2011

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2011		M <sup>(1)</sup>		25,000	A	\$ 55.97
Common Stock	05/26/2011		M <sup>(1)</sup>		2,200	A	\$ 55.97
Common Stock	05/26/2011		M <sup>(1)</sup>		5,975	A	\$ 53.43
Common Stock	05/26/2011		S <sup>(1)</sup>		28,544	D	\$ 92.9827 (2) (3)
Common Stock	05/26/2011		S <sup>(1)</sup>		4,631	D	\$ 8,820 93.4974

Edgar Filing: LEAMING NANCY - Form 4

(3) (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 55.97	05/26/2011		M <sup>(1)</sup>	25,000	<sup>(5)</sup> 01/08/2018	Common Stock	25,000
Stock Option (Right to Buy)	\$ 55.97	05/26/2011		M <sup>(1)</sup>	2,200	01/08/2009 <sup>(6)</sup> 01/08/2018	Common Stock	2,200
Stock Option (Right to Buy) <sup>(7)</sup>	\$ 53.43	05/26/2011		M <sup>(1)</sup>	5,975	06/03/2010 06/02/2019	Common Stock	5,975

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LEAMING NANCY BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493		X		

## Signatures

Aras Lapinskas, Attorney in Fact for Nancy L.  
Leaming

05/27/2011

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise/Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) This represents the weighted average price for shares sold at a range between \$92.41 (low) and \$93.40 (high).
- (3) Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- (4) This represents the weighted average price for shares sold at a range between \$93.41 (low) and \$93.60 (high).
- (5) The stock options become exercisable in three (3) equal annual installments, commencing one year after the grant date of 01/08/2008.
- (6) Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc.
- (7) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.